HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


David Wallace

Deputy Editor

Having previously worked in the European chemicals industry, Dave has now spent almost a decade with Generics bulletin. Bringing his background and education in law to bear on industry litigation - as well as national legislative and regulatory affairs - he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and judges the annual Global Generics & Biosimilars Awards. A French speaker, Dave enjoys music - with a love of the piano - and visual arts.
Set Alert for Articles By David Wallace

Latest From David Wallace

Genix Acquires 30 Ophthalmic Dossiers In Canada

Canadian firm Genix has acquired 30 ophthalmic generic dossiers from Canagen. Genix expects to begin commercialization from 2022.

Deals Generic Drugs

Lilly's Basaglar Becomes A Blockbuster

Quarterly global Basaglar sales rose above $300m for the first time in the fourth quarter of 2019, with full-year turnover pushing the insulin glargine hybrid well into blockbuster territory.

Sales & Earnings Value-Added Medicines

UK Nefopam Prices Continue To Cause Pain

Continuing UK price rises were seen for nefopam in January, according to the latest figures from market researcher WaveData.

Market Intelligence United Kingdom

Meitheal Reveals Manufacturing Expansion Plans

Meithal Pharmaceuticals has revealed future plans to expand its manufacturing capabilities as the US FDA approved a new vial manufacturing line that will double the firm’s capacity to supply the US market.

Manufacturing Strategy

Towa Hits Profit Target Three Months Early

Japan’s Towa has almost achieved its full-year operating profit goal in the first nine months of its financial year thanks to lower costs.

Sales & Earnings Strategy

Davis Steps Down As AAM’s Chief

The AAM is now searching for new leadership after Chip Davis announced his resignation as president and CEO of the US off-patent industry association.

Leadership United States
See All